Loughborough, England, September 17, 2021 (GLOBE NEWSWIRE) – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and marketing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces, that Dr. Osama Hamdy, MD, PhD, has joined the Advisory Board as a consultant and is expected to participate in and advise on key opinion leader studies in both diabetes and metabolic health in the near future using Nemaura’s glucose monitoring technology.
Dr. Hamdy is Senior Endocrinologist and Medical Director of the Obesity Clinic Program at Joslin Diabetes Center and Associate Professor of Medicine at Harvard Medical School. Dr. Hamdy is a globally recognized thought leader in obesity management for diabetes, medical nutrition, and digital health. Many of his discoveries and innovations are currently shaping these fields. His professional work focuses on understanding the metabolic and cardiovascular benefits of lifestyle changes and weight loss. He is currently investigating the cardiovascular benefits of short and long-term weight loss in obese people with and without type 2 diabetes.
“We are very excited to have a practicing clinician who has changed the real world treatment of diabetes management as a consultant for some upcoming KOL trials,” said Dr. Faz Chowdhury, CEO of Nemaura. “These studies will enable us to better influence patient health and we expect the advice and input of Dr. Hamdy help us provide non-invasive treatment options that further enrich people’s lives. “
Dr. Hamdy has translated the successful clinical research findings from two landmark diabetes studies into a clinical practice model through the creation of Joslin’s Why WAIT (Weight Achievement and Intensive Treatment) program, which serves in part as the foundation for Nemaura’s lifestyle program, BEAT® Diabetes .
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology company that develops and markets non-invasive portable diagnostic devices. The company currently markets SugarBEAT® and proBEAT ™. SugarBEAT®, a CE-certified Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) that provides actionable insights from real-time glucose readings and daily glucose trend data that can help people with diabetes and prediabetes avoid the onset of diabetes better to manage, reverse and prevent. Nemaura has submitted a PMA (Premarket Approval Application) for SugarBEAT® to the US FDA. proBEAT ™ combines non-invasive glucose data processed with artificial intelligence and a digital subscription service for the healthcare sector and was launched in the US as a general wellness product as part of its BEAT®diabetes program.
The company is at the intersection of the global type 2 diabetes market, which is projected to reach nearly $ 59 billion by 2025, the prediabetes market, which is more than $ 50 billion, and wearable health tech Weight loss and wellness applications sector estimated to reach $ 60 billion by 2023.
More information is available at www.NemauraMedical.com.